Breaking News, Collaborations & Alliances

Summit Therapeutics Grants Eurofarma Rights in Latin America

For the licensing and commercialization for precision antibiotic ridinilazole

Summit Therapeutics has entered into an exclusive license and commercialization agreement granting Eurofarma rights in Latin America to Summit’s precision antibiotic ridinilazole in development for the treatment of CDI. Summit retains commercialization rights in all other countries.   Ridinilazole is a targeted antibiotic that has the potential as a frontline therapy to treat initial infection and preserve patients’ microbiomes to reduce the rate of recurrent CDI.    “Eurofarma’s...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters